Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093403 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Bhavana Bhatnagar.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02093403: Completed Phase 1 study, sponsored by Bhavana Bhatnagar.
NCT02093403 is a Phase 1 study that has completed, run by Bhavana Bhatnagar. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02093403, a Phase 1 study, has completed, sponsored by Bhavana Bhatnagar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of Selinexor when given together with decitabine in treating patients with acute myeloid leukemia that has returned after treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as decitabine and Selinexor, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG decitabine
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-11-26 |
| Phase | Phase 1 |
What the finished NCT02093403 record still lists
NCT02093403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02093403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02093403 about?
NCT02093403 is a clinical study titled "Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the side effects and best dose of Selinexor when given together with decitabine in treating patients with acute myeloid leukemia that has returned after treatment (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as decitabine and S...
What is the current status of trial NCT02093403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-03. Estimated completion is 2016-11-26.
What interventions are being tested in trial NCT02093403?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), decitabine (DRUG), selinexor (DRUG).
Who is sponsoring clinical trial NCT02093403?
This trial is sponsored by Bhavana Bhatnagar, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02093403's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia